Study to Assess Safety & Tolerability of AZD2281 in Combination With Bevacizumab in Patients With Advanced Solid Tumours

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

November 30, 2009

Conditions

Neoplasm Metastasis

Interventions

DRUG

AZD2281

Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing

DRUG

Bevacizumab

IV administration10 mg/kg every 14 days

Trial Locations (2)

Research Site, Manchester

Research Site, Oxford